Open Access
Effectiveness of Nonpharmacological Interventions for the Management of Neuropsychiatric Symptoms in Patients With Dementia
TLDR
The cumulative research to date on the impact of nonpharmacologic interventions for NPS among patients with dementia indicates that interventions that address behavioral issues and unmet needs and that include caregivers or bright light therapy may be efficacious.Abstract:
Recent reports documenting limited evi-dence supporting the use of pharmacological interven-tions for neuropsychiatric symptoms (NPS) and in-creased risk of death, the black box warnings against theuseofatypicalantipsychoticdrugsinolderadults,andOm-nibus Budget Reconciliation Act regulations suggest theneedtoevaluatetheusefulnessofnonpharmacologicalin-terventions in the management of NPS of dementia.read more
Citations
More filters
Journal ArticleDOI
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad,Bengt Winblad,Philippe Amouyel,Sandrine Andrieu,Clive Ballard,Carol Brayne,Henry Brodaty,Angel Cedazo-Minguez,Bruno Dubois,David Edvardsson,David Edvardsson,Howard Feldman,Laura Fratiglioni,Giovanni B. Frisoni,Serge Gauthier,Jean Georges,Caroline Graff,Caroline Graff,Khalid Iqbal,Frank Jessen,Frank Jessen,Gunilla Johansson,Linus Jönsson,Miia Kivipelto,Miia Kivipelto,Martin Knapp,Francesca Mangialasche,René J. F. Melis,Agneta Nordberg,Agneta Nordberg,Marcel G. M. Olde Rikkert,Chengxuan Qiu,Thomas P. Sakmar,Thomas P. Sakmar,Philip Scheltens,Lon S. Schneider,Reisa A. Sperling,Lars O. Tjernberg,Gunhild Waldemar,Anders Wimo,Henrik Zetterberg,Henrik Zetterberg +41 more
TL;DR: This poster aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the physical and cognitive properties of Alzheimer's disease and other dementias.
Journal ArticleDOI
Dissemination and publication of research findings: an updated review of related biases.
Fujian Song,S Parekh,Lee Hooper,Yoon K. Loke,Jonathan J. Ryder,Alex J. Sutton,Caroline B. Hing,Chun Shing Kwok,C Pang,Ian Harvey +9 more
TL;DR: There was convincing evidence that outcome reporting bias exists and has an impact on the pooled summary in systematic reviews, and empirical evidence suggests that published studies tended to report a greater treatment effect than those from the grey literature.
Journal ArticleDOI
Meta-Analysis of Nonpharmacological Interventions for Neuropsychiatric Symptoms of Dementia
TL;DR: Nonpharmacological interventions delivered by family caregivers have the potential to reduce the frequency and severity of behavioral and psychological symptoms of dementia, with effect sizes at least equaling those of pharmacotherapy, as well as to reduce caregivers' adverse reactions.
Journal ArticleDOI
ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia
Dilip V. Jeste,Dan G. Blazer,Daniel E. Casey,Thomas W. Meeks,Carl Salzman,Lon S. Schneider,Pierre N. Tariot,Kristine Yaffe +7 more
TL;DR: There is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms.
Journal ArticleDOI
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Yonas E. Geda,Lon S. Schneider,Laura N. Gitlin,David S. Miller,Gwenn S. Smith,Joanne Bell,Jovier D. Evans,Michael K. Lee,Anton P. Porsteinsson,Krista L. Lanctôt,Paul B. Rosenberg,David L. Sultzer,Paul T. Francis,Henry Brodaty,Prasad P. Padala,Prasad P. Padala,Chiadikaobi U. Onyike,Luis Agüera Ortiz,Sonia Ancoli-Israel,Donald L. Bliwise,Jennifer L. Martin,Michael V. Vitiello,Kristine Yaffe,Phyllis C. Zee,Nathan Herrmann,Robert A. Sweet,Robert A. Sweet,Clive Ballard,Ni A. Khin,Cara Alfaro,Patrick S. Murray,Patrick S. Murray,Susan K. Schultz,Constantine G. Lyketsos +33 more
TL;DR: An overview of neuropsychiatric symptoms in Alzheimer's disease is presented, followed by syndrome‐specific synthetic reviews and recommendations prepared by NPS‐PIA workgroups on depression, apathy, sleep, agitation, and psychosis.
References
More filters
Journal ArticleDOI
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
TL;DR: This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
Book
Single-Case Research Designs: Methods for Clinical and Applied Settings
TL;DR: Now thoroughly updated in its second edition, acclaimed author Alan E. Kazdin's Single-Case Research Designs provides a notable contrast to the quantitative methodology approach that pervades the biological and social sciences.
Book
Single Case Experimental Designs: Strategies for Studying Behavior Change
TL;DR: In this paper, a plain-language guide to the lean production system delivers a comprehensive insider's view of lean manufacturing, focusing on three basic questions of quality improvement: What do you want to accomplish, what do we want to achieve, and how to apply the four basic management elements of planning, organizing, directing/coaching, and controlling.
Journal ArticleDOI
Defining Empirically Supported Therapies
TL;DR: It is suggested that, in evaluating the benefits of a given treatment, the greatest weight should be given to efficacy trials but that these trials should be followed by research on effectiveness in clinical settings and with various populations and by cost-effectiveness research.
Journal ArticleDOI
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
TL;DR: Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.